National Institutes of Health

Description

Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), encourages research grant applications from institutions/organizations for the development and validation of biomarkers for: a) early detection, prediction of progression, and recurrence of hematopoietic malignancies, especially in high-risk individuals; and, b) for risk assessment of primary and secondary hematopoietic malignancies. This FOA is also encourages the development and improvement of specific technologies and methods for quantitative detection of novel biomarkers associated with hematopoietic malignancies. Mechanism of Support. This FOA uses the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-09-198 that encourages applications under the NIH Exploratory/Developmental (R21) Grant mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Who can apply

• State governments
• Public and State controlled institutions of higher education
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV